Last updated: July 5, 2026
What is the litigation status of Pacira Pharmaceuticals, Inc. v. Evenus Pharmaceuticals Laboratories Inc. (2:23-cv-02367)?
Status (as of the latest docket-derived information available here): No complete case-history record (docket events, dates, filings, claim construction, or dispositive orders) is provided in the input. Under the operating constraint, a litigation-specific summary with accuracy cannot be produced.
What patents are at issue in Pacira v. Evenus (2:23-cv-02367)?
Answer: Not determinable from the provided information. A correct identification requires the complaint, infringement contentions, or the ANDA/BLA-linked Orange Book listing tied to the docket. No such patent-identifying materials were supplied.
What claims (formulation, method-of-use, or manufacturing) does Pacira allege in the Evenus case?
Answer: Not determinable from the provided information. Claim scope depends on the asserted patent(s), the specific product(s), and the infringement theory (e.g., Section viii carve-out, inducement, contributory infringement, or process infringement).
When did Pacira file suit, and what is the litigation timeline impact on FDA exclusivity and design-around windows?
Answer: Not determinable from the provided information. The filing date alone is not enough to map: (i) whether this is an ANDA Paragraph IV action, (ii) any statutory stays, (iii) any 180-day exclusivity interactions, or (iv) whether the case is linked to a settlement-triggered generic launch calendar.
What is the Orange Book status context for the underlying Pacira product that Evenus sought to compete with?
Answer: Not determinable from the provided information. Orange Book status requires the drug name, application number, and the listed patents in force at the relevant FDA milestone.
What is the Paragraph IV and 30-month stay posture in the Pacira v. Evenus case?
Answer: Not determinable from the provided information. A Paragraph IV case requires the ANDA number and the statutory stay start and expiration mechanics tied to the filing and notice letter.
How strong is Pacira’s patent estate likely to be in this case?
Answer: Not determinable from the provided information. Strength requires: the asserted patent family(s), claim breadth, prosecution history, expiration dates, and known prior art or PTAB history.
What defenses has Evenus raised in the 2:23-cv-02367 litigation (invalidity, non-infringement, carve-outs)?
Answer: Not determinable from the provided information. Defense themes depend on the answer, Rule 12 motions, invalidity contentions, and any claim construction briefs.
Did the parties reach a settlement agreement or consent judgment, and what launch terms control?
Answer: Not determinable from the provided information. Settlement terms require docket confirmation of dismissal, stipulation, or consent judgment and the agreed-at-launch covenants.
Which court orders and procedural milestones matter most to generic entry risk here?
Answer: Not determinable from the provided information. Milestones that change risk include: claim construction rulings, summary judgment, injunction outcomes, and any compliance orders tied to design-arounds.
How does this case affect biosimilar or generic entry risk for competitors?
Answer: Not determinable from the provided information. This analysis requires whether the underlying product is a small molecule vs. biologic, and whether the asserted rights block generic manufacturing, labeling, or both.
Key Takeaways
- A litigation summary and analysis for Pacira Pharmaceuticals, Inc. v. Evenus Pharmaceuticals Laboratories Inc. (2:23-cv-02367) cannot be produced from the provided input because no docket- or pleading-level facts (asserted patents, claims, dates, orders, or settlement terms) are included.
FAQs
- What information from a federal patent case docket is required to identify the asserted patents?
- How do claim construction outcomes typically shift non-infringement invalidity leverage in Paragraph IV cases?
- What terms in a settlement agreement control the first generic launch date?
- How do 180-day exclusivity and the 30-month stay interact with dismissal timing?
- What is the typical impact of amended labels or product design-arounds on infringement theories?
References
No sources were provided or cited in the input.
